Latest Breaking News On - Between jun - Page 1 : comparemela.com

Positron emission tomography-guided treatment strategy may reduce need for chemotherapy for patients with HER2+ breast cancer

1. 3-year invasive disease-free survival among the PET-based treatment group was 94.8%. 2. There were fewer treatment-related and serious adverse events among patients in the PET-based group compared to the non-PET-based group. Evidence Rating Level: 1 (Excellent) Study Rundown: Human epidermal growth factor receptor 2-positive (HER2-positive) breast cancers are associated with a high risk of

Rating levelAdvanced triple negative breastBetween jun

#VisualAbstract: Pembrolizumab enhances progression-free survival in patients with locally advanced cervical cancer

#VisualAbstract: Pembrolizumab enhances progression-free survival in patients with locally advanced cervical cancer
2minutemedicine.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 2minutemedicine.com Daily Mail and Mail on Sunday newspapers.

Rating levelResponse evaluation criteriaSolid tumoursBetween jun

Novel transcatheter heart valve may be effective for management of high-risk aortic regurgitation

1. The 30-day composite primary safety endpoint of > 40.5% was achieved for Trilogy TAVI. 2. 8% of patients who underwent Trilogy TAVI had passed at the 1-year follow-up. Evidence Rating Level: 1 (Excellent) Study Rundown: Surgery remains the primary intervention for native aortic regurgitation, but high-risk patients lack optimal alternatives. Traditional transcatheter heart valves

Jenavalve technologyRating levelSurgical treatmentBetween junCardiac surgeryHeart valvesProsthetic valvesTranscatheter aortic valve implantationTranscatheter aortic valve replacement tavrValvular diseaseChronic diseaseImaging and intervention

Pembrolizumab enhances progression-free survival in patients with locally advanced cervical cancer

1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly higher rates of grade 3 or higher adverse events compared to the placebo-chemoradiotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Pembrolizumab has demonstrated efficacy in advanced cervical cancer, prompting an investigation into its potential

Rating levelResponse evaluation criteriaSolid tumoursMetastatic cervicalBetween junCervical cancerGynecologic oncologyLocally advanced cervical cancerChronic disease

High dose aflibercept reduced treatment burden in patients with diabetic macular edema

1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events were comparable across all intervention groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Diabetic macular oedema (DMO) leads to vision loss in 5% of patients with diabetes. Anti-vascular endothelial growth factor (anti-VEGF) medications, such as

Rating levelBevacizumab firstDiabetic macularBetween jun